Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Tomato who wrote (825)	2/16/2005 11:14:21 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

MUCL, one of the two subsidiary companies of Extent Ind., was up 10.53% as it was able to close above its Feb. & Jan. Hs. The volume of 2,731,904 was the highest in many months and larger than the 1,800,293 traded on Jan.11 The stock has been on a near term up-trend since Jan.5 when the up-move started from the $0.20 level.<g> The stock, as well as ASTM's, have been benefiting by the fact that ASCs are not affected by the recent setbacks on ESCs. (It is expected that the demand for ASCs will increase after stem cell experts said recently that all federally approved lines of ESCs are contaminated with a non-human molecule that could be tumorogenic.<g>) biz.yahoo.com For the 9 months MUCL's revenues reportedly increased 82% to $534Ks, but its loss increased to $3.2M from $1.2M in 2003.<g> In spite of its $0.01 cash/share, it has a Debt/Equity ratio of 0.324 <g>(Insiders reportedly hold around 35% of the shares.) The stock needs to close above its early Apr. H of $0.48 before it can test its Mar. H at $0.56 or its Feb. H at $0.68 but at any rate, it is up a 100% so far in 2005.<g> bigcharts.marketwatch.com bigcharts.marketwatch.com Bernard

To: Tomato who wrote (825)	2/17/2005 1:26:42 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3722

Wayne: it's on Avalon's sell list. every known dirty trick and some new ones will be used against it. it's not just passive selling. but I do presume that passive selling is the primary south driver. haven't a clue why someone would sell, now that 6827 is in clinical testing. bewildering to me, given the leveraged pipe and a profitable business that fits the decade. but I'm allowed to be bewildered. it will again be interesting to see short interest this month. it's amazing, given our advanced technologies, that we need to wait a puking month to see short interest data, and then we get old data. up 170% in last two reports. cheers! Rick